Granulomatosis de Wegener, una afección poco frecuente / Wegener's granulomatosis, a rare condition

Introducción: la granulomatosis de Wegener es una vasculitis sistémica, poco frecuente, cuyo sustrato etiopatogénico es la inflamación de los vasos sanguíneos impidiendo la libre circulación del flujo sanguíneo. Clinicamente se caracteriza por presencia de manifestaciones respiratorias, nasales, auditivas y renales; frecuentemente se asocian trastornos infecciosos y alérgicos. Objetivo: socializar los principales elementos etiopatogénicos, manifestaciones clínicas y exámenes complementarios que permiten definir el granulomatosis de Wegener. Caso clínico: se presenta el caso de una paciente de 32 años de edad la cual es referida desde la atención primaria de salud, por presentar manifestaciones clínicas y de laboratorio que permiten confirmar el diagnóstico de una granulomatosis de Wegener. Conclusiones: la granulomatosis de Wegener es una rara enfermedad que, aunque se presenta fundamentalmente en pacientes femeninas entre 40 y 50 años, puede presentarse en pacientes de cualquier edad sin distinguir preferencia por el sexo. Sus principales manifestaciones clínicas son la toma respiratoria y renal acompañada de manifestaciones generales. El uso de esteroides constituye la piedra angular del tratamiento, al cual se adicionan medicamentos para el control de la enfermedad como es el caso del methotrexate.

Introduction: Wegener's granulomatosis is a rare systemic vasculitis, whose etiopathogenic substrate is the inflammation of the blood vessels, preventing the free circulation of blood flow. Clinically it is characterized by the presence of respiratory, nasal, auditory and renal manifestations; Infectious and allergic disorders are frequently associated. Objective: to socialize the main etiopathogenic elements, clinical manifestations and complementary examinations that allow us to define Wegener's granulomatosis. Clinical case: the case of a 32-year-old female patient is reported from primary health care, due to clinical and laboratory manifestations that confirm the diagnosis of Wegener's granulomatosis. Conclusions: Wegener's granulomatosis is a rare disease that, although it occurs mainly in female patients between 40 and 50 years, can occur in patients of any age without distinguishing preference for sex. Its main clinical manifestations are respiratory and renal uptake accompanied by general manifestations. The use of steroids is the cornerstone of the treatment, to which are added medications for the control of the disease such as methotrexate.

Linfoma no Hodgkin de amígdalas en un paciente con lupus eritematoso sistémico / Non-Hodgkin's lymphoma of tonsils in a patient with systemic lupus erythematous

Introducción: las enfermedades reumáticas aumentan el riesgo de aparición de distintas comorbilidades y estado de salud inadecuado en los pacientes. Dentro de estas comorbilidades las más peligrosas, por la frecuencia que se producen y por el desenlace final de las mismas lo constituyen las enfermedades neoplásicas. Objetivos: socializar los elementos clínicos, de laboratorio e histopatológicos que permiten la sospecha clínica y el diagnóstico de linfoma no Hodgkin en pacientes con enfermedades reumáticas. Caso clínico: paciente femenina de 54 años de edad, con diagnóstico de lupus eritematoso sistémico y síndrome de Sjögren secundario que acude con manifestaciones clínicas dadas por sudores nocturnos profusos, toma del estado general, fiebre vespertina y adenopatías cervicales. Se le realiza el diagnóstico de linfoma no Hodgkin en amígdala derecha. Conclusiones: las enfermedades reumáticas aumentan el riesgo de aparición de enfermedades neoplásicas. El seguimiento periódico, la adherencia farmacológica y el monitoreo constante de manifestaciones generales y elementos de sospecha de procesos malignos, son las acciones fundamentales que se pueden realizar para prevenir o diagnósticas precozmente la aparición de afecciones neoplásicas en pacientes reumáticos(AU)

Introduction: rheumatic diseases increase the risk of the appearance of different comorbidities and inadequate health status in patients. Within these comorbidities the most dangerous, by the frequency that occur and by the final outcome of them are neoplastic diseases. Objectives: to socialize the clinical, laboratory and histopathological elements that allow clinical suspicion and the diagnosis of non-Hodgkin's lymphoma in patients with rheumatic diseases. Case report: A 54-year-old female patient with a diagnosis of systemic lupus erythematous and secondary Sjogren's syndrome who presented with clinical manifestations due to profuse nocturnal sweats, general condition, afternoon fever and cervical lymphadenopathy. He is diagnosed with non-Hodgkin's lymphoma in the right amygdala. Conclusions: rheumatic diseases increase the risk of the appearance of neoplastic diseases. The periodic follow-up, the pharmacological adherence and the constant monitoring of general manifestations and elements of suspicion of malignant processes, are the fundamental actions that can be performed to prevent or early diagnosis the appearance of neoplastic affections in rheumatic patients(AU)

Effects of nitric oxide inhibitors in mice with bladder outlet obstruction

ABSTRACT Purpose To investigate the lower urinary tract changes in mice treated with L-NAME, a non-selective competitive inhibitor of nitric oxide synthase (NOS), or aminoguanidine, a competitive inhibitor of inducible nitric oxide synthase (iNOS), after 5 weeks of partial bladder outlet obstruction (BOO), in order to evaluate the role of constitutive and non-constitutive NOS in the pathogenesis of this experimental condition. Materials and Methods C57BL6 male mice were partially obstructed and randomly allocated into 6 groups: Sham, Sham + L-NAME, Sham + aminoguanidine, BOO, BOO + L-NAME and BOO + aminoguanidine. After 5 weeks, bladder weight was obtained and cystometry and tissue bath contractile studies were performed. Results BOO animals showed increase of non-voiding contractions (NVC) and bladder capacity, and also less contractile response to Carbachol and Electric Field Stimulation. Inhibition of NOS isoforms improved bladder capacity and compliance in BOO animals. L-NAME caused more NVC, prevented bladder weight gain and leaded to augmented contractile responses at muscarinic and electric stimulation. Aminoguanidine diminished NVC, but did not avoid bladder weight gain in BOO animals and did not improve contractile responses. Conclusion It can be hypothesized that chronic inhibition of three NOS isoforms in BOO animals leaded to worsening of bladder function, while selective inhibition of iNOS did not improve responses, what suggests that, in BOO animals, alterations are related to constitutive NOS.

Enfermedad de stargardt o degeneración macular de stargardt / Stargardt disease or stargardt macular degeneration

La degeneración macular de Stargardt es considerada una enfermedad rara pues se presenta un caso por cada 10.000 personas (1).Es de transmisión hereditaria de un patrón autosómico recesivo. Está provocada por una mutación del gen ABCA4, que tiene una función transportadora a través de la membrana de las células fotorreceptoras. Hay 558 mutaciones diferentes que pue-den originar el mal (2).La enfermedad Stargardt y Fundusflavima-culatus son la misma enfermedad, siendo el segundo, un estado más avanzado de almacenamiento de lipofucsina (3).CASO CLINÍCOPaciente de 16 años de edad acude a consulta de medicina preventiva refiriendo presentar disminución de agudeza visual, antecedentes de miopía y astigmatismo con debida corrección de error refracta-rio. Actualmente presenta disminución de agudeza visual más notoria en zona central, usando así su visión periférica. Agudeza visual: 20/100. Campimetría: hay es-cotomas. Angiofluorgrafía: muestra una coroides oscura por depósitos de lipofuscina del epitelio pigmentario de la retina dando como resultado la enfermedad de Stargardt.

The Stargardt Macular degeneration is con-sidered a rare disease; one case per 10,000 people is presented. (1)It is Inheritance and it is given an autoso-mal recessive pattern. It is caused by a mu-tation of ABCA4 gene, which has a trans-port function through the membrane of the photoreceptor cells. There are 558 different mutations that can cause it. (2)The Stargardt disease and fundusflavima-culatus are the same disease, the second is a more advanced state of lipofuscin sto-rage. (3)CASE REPORTA 16 years old patient attends to the pre-ventive health referring to have a decrea-sed visual acuity, history of myopia and as-tigmatism with refractive error correction. Currently has more noticeable decrease in central visual acuity, so using your periphe-ral vision. Visual acuity 20/100 Campimetry: there is noscotoma, angiofluorgrafia: it dis-plays a dark choroid by deposits of lipofus-cin of the pigment epithelium of the retina which results the Stargardt disease.

Effect of acute administration of sildenafil to rats with detrusor overactivity induced by chronic deficiency of nitric oxide

Purpose Recently, the effect of phosphodiesterase inhibitors (PDE5i) in the lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia have been studied thoroughly. However, it remains unclear how the PDE5i improve LUTS. Therefore, the aim of the present study was to evaluate the potential of acute administration of the PDE5i sildenafil to improve detrusor overactivity (DO) induced by Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME), an nitric oxide sinthase (NOS) inhibitor, in rats. Materials and Methods Twenty-seven MALE adult Wistar Rats were divided into the following groups: (1) control, (2) L-NAME, (3) sildenafil alone, and (4) L-NAME + sildenafil. The NOS blocker L-NAME (20 mg/rat/day) was given in the drinking water. Sildenafil (100µg/kg) was administrated intravenously (i.v.) acutely, diluted in cremophor, propylene glycol and water. All animals underwent to anesthetized cystometograms. Results The chronic and systemic administration of L-NAME markedly increased the number of non voiding contractions (2.62 (± 0.89)), and frequency of micturition (1.97 (± 0.78)), as well increased volume threshold (2.83 mL (± 1.64)) compared with control group, the number of non voiding contractions (1.17 (± 0.75)), frequency of micturition (1.08 (± 0.65)) and volume threshold (1.16 mL (± 0.38)), p < 0.001, p = 0.01, and p = 0.04, respectively. Sildenafil infusion decreased the number of micturition cycles significantly from the baseline to end point (-0.93 (± 0.34)) in nitric oxide (NO) deficient animals compared with sildenafil infusion alone (control) in animals with normal NO level (0.13 (± 0.25)), p = 0.03. Conclusion Systemic reduction of nitric oxide causes detrusor overactivity and acute infusion of sildenafil reduces the number of micturition cycles in chronic NO-deficient rats. .

Administração de BAY 41-2272 previne disfunção vesical em ratos deficientes de oxido nítrico / Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats

Objective: to evaluate the protective effects of BAY 41-2272, a soluble guanylate cyclase activator, on changes in cystometric parameters in rats deficient in nitric oxide (NO). Methods: Rats were divided into the following groups: (a) control; (b) DMSO; (c) L-NAME; (d) BAY 41-2272 alone; (e) L-NAME + BAY 41-2272. The NO synthase blocker L-NAME (20 mg/rat/day) was given in drinking water concomitantly or not with BAY 41-2272 (10 mg/kg/day, given by gavage). Results: Chronic L-NAME treatment markedly increased the mean arterial blood pressure, and co-treatment with BAY 41-2272 nearly reversed L-NAME-induced rise on mean arterial blood pressure. Non-void contractions were significantly increased in L-NAME group (0.90 ± 0.1 number/minute) compared with either DMSO or control group (0.49 ± 0.1 number/minute), which were prevented by co-treatment with BAY 41-2272 (0.56 ± 025 number/minute; p < 0.05). The threshold and peak pressure increased by 70 and 44%, respectively, after chronic L-NAME treatment, while co-treatment with BAY 41-2272 largely attenuated both effects (27 and 22% increase, respectively). The frequency of micturition cycles decreased by about of 50% in L-NAME-treated rats compared with control animals, and co-treatment with BAY 41-2272 normalized this parameter. Conclusions: Our data show that long-term oral administration of BAY 41-2272 counteracts the bladder dysfunction seen in NO-deficient rats, indicating that restoration of the NO-cGMP pathway by this compound may be of beneficial value to treat bladder symptoms.

Objetivo: avaliar os efeitos protetores do BAY 41-2272, um ativador solúvel da guanilato ciclase, sobre alteração dos parâmetros citométricos em ratos deficientes de óxido nítrico (NO). Métodos: os ratos foram divididos nos seguintes grupos: (a) controle; (b) DMSO (c) L-NAME; (d) BAY 41-2272 isolado; (e) L-NAME + BAY 41-2272. O bloqueador da NO-sintase L-NAME (20 mg/rato/dia) foi ministrado na água de beber, concomitantemente ou não com o BAY 41-2272 (10 mg/kg/dia, ministrado por gavagem). Resultados: o tratamento crônico com L-NAME aumentou de forma acentuada a pressão arterial média, e o co-tratamento com BAY 41-2272 quase reverteu o aumento na pressão arterial média induzido por L-NAME. Contrações não esvaziadoras da bexiga mostraram-se significativamente aumentadas no grupo L-NAME (0,90 ± 0,1 número/minuto) comparadas com DMSO ou grupo controle (0,49 ± 0,1 número/minuto), que foram evitadas pelo co-tratamento com BAY 41-2272 (0,56 ± 0,25 número/minuto; p < 0,05). O limiar e o pico de pressão aumentaram em 70 e 44%, respectivamente, após o tratamento crônico com L-NAME, enquanto o co-tratamento com BAY 41-2272 atenuou muito ambos os efeitos (27 e 22% de aumento, respectivamente). A frequência de ciclos de micção diminuiu em 50% nos ratos tratados com L-NAME em comparação aos animais controle; o cotratamento com BAY 41-2272 normalizou esse parâmetro. Conclusões: nossos dados mostram que a administração oral a longo prazo de BAY 41-2272 contrapõe-se à disfunção de bexiga vista em ratos deficientes de NO, o que sugere que a restauração da via da NO-cGMP por esse composto pode ter valor benéfico para tratar sintomas vesicais.